ACCC logo
Facebook  LinkedIn  Twitter  ACCC Youtube Channel  ACCCBuzz blog

Association of Community Cancer Centers

The leading education and advocacy organization for the multidisciplinary cancer team

ACCCBuzz Blog  Find a Cancer Program  Log in to MyNetwork

Home > Mediaroom > Press Releases > 2008 > Cancer Vaccines: How Close Are We to Their Widespread Use?

Lori Gardner, Senior Director
Communications & Marketing
301.984.9496 ext. 226

ACCC News Release

For Immediate Release: April 4, 2008

Cancer Vaccines: How Close Are We to Their Widespread Use?

ROCKVILLE, Md.—Preventive and therapeutic cancer vaccines are on the fast-track to development. How do they work? How safe are they? A panel of national experts will explore which preventive cancer vaccines are already being used and promoted, and how close we are to therapeutic vaccines against melanoma, prostate cancer, lymphomas, and head and neck cancers, among others. They’ll look at the challenges to widespread use of cancer vaccines, including education, cost, and duration of effect.

Attention will focus on preventive vaccines against cervical cancer. Seventy percent of cervical cancers are caused by the two most common human papillomaviruses: HPV-16 and HPV-18. The association between HPV and cervical cancer is higher than that between smoking and lung cancer. And yet, while the U.S. Food and Drug Administration has already approved the cancer prevention vaccine HPV-16/18/6/11—and others are in the pipeline, there is a widespread lack of understanding between the association of HPV infection to cervical abnormalities as well as to other malignancies, including head and neck, vaginal, anal, and penile cancers. What are the barriers to using the HPV vaccine? Are we reaching the women that need the vaccine the most? Are women understanding that the vaccine is another piece, not a replacement, for cervical cancer prevention? Explore the answers.

Vaccine clinics are already being established. Learn more about vaccine clinics and how they can be helpful as a community service for physicians and patients.

1:00 pm–2:30 pm
New Technology Panel: The Present and Future of Cancer Vaccines
Moderator: Clifford Goodman, PhD, The Lewin Group
Panel: Natalie Sacks, MD, Cell Genesys; Soldano Ferrone, MD, PhD, Roswell Park Cancer Institute; Kenneth A. Foon, MD, University of Pittsburgh Cancer Institute

3:00 pm–4:00 pm
Concurrent Technology Sessions

Technology I: Prostate Cancer Vaccines
Speaker: Natalie Sacks, MD, Cell Genesys, Inc.
Technology II: Melanoma Cancer Vaccines
Speaker: Soldano Ferrone, MD, PhD, Roswell Park Cancer Institute
Technology III: Cancer Vaccine Clinical Trials
Speaker: Kenneth A. Foon, MD, University of Pittsburgh Cancer Institute
Technology IV: Development of a Model Vaccine Center Program
Speaker: Mark H. Einstein, MD, Montefiore Medical Center

About the Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. More than 23,000 cancer care professionals from over 2,000 hospitals and practices nationwide are affiliated with ACCC. It is estimated that 65 percent of the nation's cancer patients are treated by a member of ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. For more information, visit ACCC's website at Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz.

Copyright © 2017 Association of Community Cancer Centers. All Rights Reserved.
1801 Research Boulevard, Suite 400, Rockville, MD 20850  |  Tel.: 301.984.9496  |  Fax: 301.770.1949